Galantamine hydrobromide | CAS:1953-04-4

Galantamine hydrobromide

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $10.8 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Our products had been exported to the following research institutions and universities, And still growing.

Monash University Malaysia (Malaysia)
Florida International University (USA)
Worcester Polytechnic Institute (USA)
University of Beira Interior (Portugal)

Utrecht University (Netherlands)
Texas A&M University (USA)
S.N.D.T. Women's University (India)
Mahidol University (Thailand)

Medical University of Gdansk (Poland)
Universidade do Porto (Portugal)
Helmholtz Zentrum München (Germany)
More...

Package

Featured Products

More...

L-Citruline

Catalog No: CFN90551
CAS No: 372-75-8
Price: $30/20mg

Senecionine

Catalog No: CFN00417
CAS No: 130-01-8
Price: $ /

Chrysin

Catalog No: CFN98741
CAS No: 480-40-0
Price: $40/20mg

Gypenoside L

Catalog No: CFN91854
CAS No: 94987-09-4
Price: $268/5mg

Taxifolin

Catalog No: CFN98734
CAS No: 480-18-2
Price: $30/20mg

Neochamaejasmine B

Catalog No: CFN92152
CAS No: 90411-12-4
Price: $318/5mg

Gelsemine

Catalog No: CFN99001
CAS No: 509-15-9
Price: $218/20mg

2-(3,4-Dihydroxyphenyl)ethanol

Catalog No: CFN99076
CAS No: 10597-60-1
Price: $88/20mg

Danshensu

Catalog No: CFN99539
CAS No: 22681-72-7
Price: $70/20mg

Lycorine

Catalog No: CFN90263
CAS No: 476-28-8
Price: $30/20mg

Description:

Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors.

Targets:

AChR | AChR

In vivo:

Pharm Dev Technol. 2013 Sep-Oct;18(5):1148-58.

Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology.[Pubmed: 21770841]

The objective of this study is to develop and in vivo evaluation of novel monolithic matrix mini tablets approach to control the release of Galantamine hydrobromide (GAH) in comparison with desired release profile to the Innovator formulation Razadyne(®) ER capsules.
METHODS AND RESULTS:
The direct compression method was employed for preparation of matrix mini tablets as against reservoir multiparticulate pellets of innovator formulation. The matrix swellings, dissolution similarity, mean dissolution time and dissolution efficiency of formulations were evaluated. It was found that increase in the concentration of high viscosity hydroxypropylcellulose (HPC) results reduction in release rate. The drug release was shown to be pH dependent with faster rate at lower pH. The release of GAH followed first order shifting to dissolution dependent by increase of HPC content. The formulation showed stability of drug release. In vivo prediction was done by Wagner-Nelson method. Prediction errors were estimated for Cmax and area under curve (AUC) and found to be not exceeding 15%. In vivo study in human volunteers confirmed the similarity between test and innovator formulations and pharmacokinetic values were comparable between actual and predicted.
CONCLUSIONS:
These results suggest that novel monolithic matrix approach could be suitable technique to formulate controlled release GAH.

Psychiatry Investig. 2009 Sep;6(3):204-10.

The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.[Pubmed: 20046396]

Mental fatigue, cognitive disorders, and sleep disturbances seen in chronic fatigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypoactivity seen in CFS. Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4-week administration of Galantamine hydrobromide, a selective acetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment.
METHODS AND RESULTS:
Basal levels of cortisol and DHEAS were measured in 29 untreated CFS patients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 20 healthy controls. In the patient group, four weeks after 8 mg/d Galantamine hydrobromide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 patients who stayed in study were divided into two subgroups as responders and nonresponders according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) scores. Important findings of this study are lower pre-and post-treatment cortisol levels and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, respectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which were normalized following four weeks' treatment with 8 mg/d Galantamine hydrobromide in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively).
CONCLUSIONS:
The findings of the decrease in basal DHEAS levels and DHEAS/cortisol molar ratios normalizing with galantamine treatment may give some support to the cholinergic deficit hypothesis in CFS.

Galantamine hydrobromide Description

Source:	The bulbs of Lycoris radiata.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Structure Identification:

J Pharm Biomed Anal. 2011 Apr 28;55(1):85-92.

Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide.[Pubmed: 21300511]

Galantamine hydrobromide was subjected to different stress conditions (acidic, alkaline, thermal, photolytic and oxidative). Degradation was found to occur under acidic, photolytic and oxidative conditions, while the drug was stable under alkaline and elevated temperature conditions.
METHODS AND RESULTS:
A stability-indicating reversed-phase liquid chromatographic method was developed for the determination of the drug in the presence of its degradation products. The method was validated for linearity, precision, accuracy, specificity, selectivity and intermediate precision. Additionally, the degradation kinetics of the drug was assessed in relevant cases. The kinetics followed a first order behavior in the case of acidic and photolytic degradation, while a two-phase kinetics behavior was found for the oxidative degradation.
CONCLUSIONS:
The degradation products were characterized by mass spectrometry and nuclear magnetic resonance spectroscopy. Dehydration, epimerization and N-oxidation were the main processes observed during the degradation of galantamine. Moreover, if sufficient material could be isolated the inhibitory activity against the target enzyme acetylcholinesterase was also assessed.

Product Name	Galantamine hydrobromide
Price:	$40 / 20mg
CAS No.:	1953-04-4
Catalog No.:	CFN90744
Molecular Formula:	C₁₇H₂₂BrNO₃
Molecular Weight:	368.3 g/mol
Purity:	>=98%
Type of Compound:	Alkaloids
Physical Desc.:	Powder
Source:	The bulbs of Lycoris radiata.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download:	COA MSDS SDF
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Anticholinesterase Compound Library Alkaloids Compound Library AChR Inhibitor Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.7152 mL	13.5759 mL	27.1518 mL	54.3036 mL	67.8794 mL
5 mM	0.543 mL	2.7152 mL	5.4304 mL	10.8607 mL	13.5759 mL
10 mM	0.2715 mL	1.3576 mL	2.7152 mL	5.4304 mL	6.7879 mL
50 mM	0.0543 mL	0.2715 mL	0.543 mL	1.0861 mL	1.3576 mL
100 mM	0.0272 mL	0.1358 mL	0.2715 mL	0.543 mL	0.6788 mL

CFN90331	Dihydrolycorine	6271-21-2	289.33	C₁₆H₁₉NO₄
CFN98548	Pseudolycorine	29429-03-6	289.33	C₁₆H₁₉NO₄
CFN99730	Lycorine chloride	2188-68-3	323.78	C₁₆H₁₇NO₄Cl
CFN93030	Ungeremine	72510-04-4	266.27	C₁₆H₁₂NO₃+
CFN90745	Lycoramine	21133-52-8	289.4	C₁₇H₂₃NO₃
CFN91708	O-Desmethyl galanthamine	60755-80-8	273.3	C₁₆H₁₉NO₃
CFN90743	Galantamine	357-70-0	287.4	C₁₇H₂₁NO₃
CFN90744	Galantamine hydrobromide	1953-04-4	368.3	C₁₇H₂₂BrNO₃
CFN91709	Galanthamine 10-Oxide(Galanthamine N-Oxide)	134332-50-6	303.4	C₁₇H₂₁NO₄
CFN91707	O-Acetylgalanthamine	25650-83-3	329.4	C₁₉H₂₃NO₄